Posts from January 2018

Understanding drug-drug interactions can improve drug safety

A considerable proportion of adverse drug events are caused by interactions between drugs. With an ageing population, and associated increasing multiplicity of age-related illnesses, there is an increase in the potential for increased risk of drug-drug interactions (DDIs). One way of alleviating some DDIs is by ensuring that potentially interacting drugs are taken at suitable time intervals apart. But, what is the best interval to recommend?

In a recent seminar, Keith Burkhardt of the FDA described a project using text mining to survey the landscape of information on DDIs from FDA Drug Labels. And, in particular, the FDA review division wanted to find labelling for drugs where the time separation was stated, in order to prevent potential drug safety events.

Mining Data from FDA Drug Labels: dosing regimens and time separation

The drug classes of interest included bile acid sequestrants and exchange resins (such as cholestyramine, colestipol, colesevelam, all LDL cholesterol lowering drugs), phosphate binders (e.g. sevelamer; used for patients with chronic kidney failure), and chelators (used to treat excessively high levels of lead, iron or copper in the blood; e.g. deferasirox, deferiprone). These drug classes can all alter the bioavailability of other drugs, particularly for those with a narrow therapeutic range such as warfarin or antiepileptic drugs.